MA52813A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52813A MA52813A MA052813A MA52813A MA52813A MA 52813 A MA52813 A MA 52813A MA 052813 A MA052813 A MA 052813A MA 52813 A MA52813 A MA 52813A MA 52813 A MA52813 A MA 52813A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 title 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682033P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52813A true MA52813A (fr) | 2021-04-14 |
Family
ID=68769462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052813A MA52813A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12338238B2 (fr) |
| EP (1) | EP3801500B1 (fr) |
| JP (2) | JP2021527125A (fr) |
| CN (1) | CN112839647B (fr) |
| CA (1) | CA3102645A1 (fr) |
| ES (1) | ES3028093T3 (fr) |
| MA (1) | MA52813A (fr) |
| WO (1) | WO2019236879A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019236884A1 (fr) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| CN112839647B (zh) | 2018-06-07 | 2025-09-23 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CA3123215C (fr) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs |
| EP4028013A4 (fr) | 2019-09-12 | 2023-10-18 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| WO2021108602A1 (fr) * | 2019-11-26 | 2021-06-03 | Disarm Therapeutics, Inc. | Méthodes et compositions pour la neuroprotection |
| EP4132928B1 (fr) * | 2020-04-09 | 2025-12-24 | Disarm Therapeutics, Inc. | Dérivés de pyrazole condensés comme inhibiteurs de sarm1 |
| EP4132920B1 (fr) * | 2020-04-09 | 2025-08-13 | Disarm Therapeutics, Inc. | Dérivés d' indazole comme inhibiteurs de sarm1 |
| EP4158008A4 (fr) * | 2020-05-27 | 2024-10-23 | Emendobio Inc. | Inactivation biallélique de sarm1 |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| US20250361234A1 (en) * | 2022-06-06 | 2025-11-27 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| EP4655295A1 (fr) | 2023-01-24 | 2025-12-03 | Disarm Therapeutics, Inc. | 1h-pyrazole-4-carboxamides substitués en tant qu'inhibiteurs de sarm1 |
| EP4702017A1 (fr) * | 2023-04-27 | 2026-03-04 | Sironax Ltd | Modulateurs de sarm1, préparations et leurs utilisations |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| US3506668A (en) | 1965-01-26 | 1970-04-14 | Sterling Drug Inc | Method of preparing 8-hydroxy-quinolines |
| US3429887A (en) | 1965-01-26 | 1969-02-25 | Sterling Drug Inc | 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation |
| US3429882A (en) | 1968-03-25 | 1969-02-25 | Geigy Chem Corp | 1,2,8,9-tetraazaphenalenes |
| US3539567A (en) | 1968-04-23 | 1970-11-10 | Geigy Chem Corp | 8-carboxy-1(2h) phthalazinones |
| US3624108A (en) | 1968-04-23 | 1971-11-30 | Geigy Chem Corp | 7-carboxyphthalides |
| US3761493A (en) | 1968-04-23 | 1973-09-25 | Ciba Geigy Corp | 3-dibromomethylphthalic anhydride |
| US3629251A (en) | 1968-08-12 | 1971-12-21 | Geigy Chem Corp | Derivatives of 9-aminoalkyl-1 2 8 9-tetraazaphenalenes |
| US3517014A (en) | 1969-06-16 | 1970-06-23 | Sterling Drug Inc | Method of preparing 8-hydroxyquinoline-3-carboxylic acids |
| US3711473A (en) | 1970-04-06 | 1973-01-16 | Ciba Geigy Corp | 3-hydrazino-1,2,8,9-tetraazaphenalenes |
| DE2449252A1 (de) | 1973-10-16 | 1975-04-17 | Fuji Photo Film Co Ltd | Waermeentwickelbares, lichtempfindliches material |
| US4207112A (en) | 1974-01-29 | 1980-06-10 | Fuji Photo Film Co., Ltd. | Heat developable light-sensitive materials |
| JPS50123331A (fr) | 1974-03-14 | 1975-09-27 | ||
| GB9310700D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| HK1053833A1 (zh) | 2000-04-27 | 2003-11-07 | Abbott Laboratories | 取代苯基法呢基转移酶抑制剂 |
| CA2443918C (fr) * | 2001-04-11 | 2012-06-05 | Senju Pharmaceutical Co., Ltd. | Agents contenant des inhibiteurs de la kinase rho ameliorant les troubles de la fonction visuelle |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2005102345A1 (fr) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Utilisation d'inhibiteurs de kinase rho dans le traitement de deficits auditifs, d'acouphenes et dans l'amelioration de l'equilibre corporel |
| US20060078890A1 (en) * | 2004-10-08 | 2006-04-13 | Ole Isacson | Methods for identifying parkinson's disease therapeutics |
| PT1899322E (pt) * | 2005-06-28 | 2009-11-09 | Sanofi Aventis | Derivados de isoquinolina como inibidores de rho-cinase |
| HRP20110839T1 (hr) * | 2005-07-26 | 2011-12-31 | Sanofi | Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze |
| US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
| GB0605766D0 (en) | 2006-03-22 | 2006-05-03 | Ucb Sa | Process |
| US20100004244A1 (en) | 2006-06-27 | 2010-01-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of cb2 receptor agonists for promoting neurogenesis |
| MX2009000374A (es) * | 2006-07-13 | 2009-01-27 | Novartis Ag | Uso de benzamidas substituidas con trifluorometilo en el tratamiento de trastornos neurologicos. |
| EP2307400B1 (fr) * | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibiteurs de la pi3 kinase |
| JP2010053073A (ja) | 2008-08-28 | 2010-03-11 | Sankyo Kasei Kk | ハロゲン化イソキノリン類の製造方法 |
| SG10201407409WA (en) * | 2009-02-06 | 2015-01-29 | Elan Pharm Inc | Inhibitors of jun n-terminal kinase |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| WO2013005157A1 (fr) | 2011-07-05 | 2013-01-10 | Lupin Limited | Dérivés de sulfone et leur utilisation en tant que modulateurs de pkm2 pour le traitement du cancer |
| DE102012019369A1 (de) * | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| DK3013804T3 (en) | 2013-06-24 | 2017-04-10 | Merck Patent Gmbh | phthalazine |
| WO2015050471A1 (fr) | 2013-10-02 | 2015-04-09 | Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" | Composés carbazole et leurs méthodes d'utilisation |
| WO2015102929A1 (fr) | 2013-12-30 | 2015-07-09 | Novartis Ag | Dérivés de sulfonamide tricycliques |
| FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2774923T3 (es) * | 2014-04-28 | 2020-07-23 | China Resources Pharmaceutical Holdings Company Ltd | Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa |
| EP3188730B1 (fr) * | 2014-09-05 | 2019-05-01 | Merck Sharp & Dohme Corp. | Dérivés de tétrahydroisoquinoléine utiles en tant qu'inhibiteurs de diacylglycéride o-acyltransférase 2 |
| WO2017121684A1 (fr) | 2016-01-14 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 2-(morpholin-4-yl)-1,7-naphthyridines substituées en 5 |
| US11357800B2 (en) | 2016-08-16 | 2022-06-14 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| JP7044789B2 (ja) * | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用 |
| CA3056551A1 (fr) | 2017-03-13 | 2018-09-20 | Impetis Biosciences Limited | Composes bicycliques fusionnes, compositions et applications correspondantes |
| WO2019236884A1 (fr) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| CN112839647B (zh) | 2018-06-07 | 2025-09-23 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN120398784A (zh) | 2018-06-07 | 2025-08-01 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN109223787A (zh) | 2018-10-04 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种喜树碱和新型酞嗪酮类化合物联合用药物组合物 |
| CN109336863A (zh) | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型酞嗪酮类btk抑制剂、制备及其应用 |
| CN109485636A (zh) | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途 |
| CN109180642A (zh) | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类btk抑制剂及其应用 |
| CN109293635A (zh) | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的p晶型及其制备方法 |
| JP7273954B2 (ja) | 2018-10-19 | 2023-05-15 | ディスアーム セラピューティクス， インコーポレイテッド | Ｎａｄ＋またはｎａｄ＋前駆体と組み合わせたｓａｒｍ１の阻害 |
| CN109172562A (zh) | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109394766A (zh) | 2018-10-31 | 2019-03-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109481441A (zh) | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109276571A (zh) | 2018-10-31 | 2019-01-29 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| CN109331018A (zh) | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| WO2021261540A1 (fr) | 2020-06-25 | 2021-12-30 | 富士フイルム株式会社 | Procédé de production de cellules épithéliales intestinales et leur utilisation |
-
2019
- 2019-06-06 CN CN201980052437.0A patent/CN112839647B/zh active Active
- 2019-06-06 JP JP2021518045A patent/JP2021527125A/ja active Pending
- 2019-06-06 MA MA052813A patent/MA52813A/fr unknown
- 2019-06-06 WO PCT/US2019/035833 patent/WO2019236879A1/fr not_active Ceased
- 2019-06-06 US US16/972,684 patent/US12338238B2/en active Active
- 2019-06-06 ES ES19816172T patent/ES3028093T3/es active Active
- 2019-06-06 CA CA3102645A patent/CA3102645A1/fr active Pending
- 2019-06-06 EP EP19816172.1A patent/EP3801500B1/fr active Active
-
2023
- 2023-11-30 JP JP2023203259A patent/JP7576145B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801500A1 (fr) | 2021-04-14 |
| EP3801500A4 (fr) | 2022-03-02 |
| ES3028093T3 (en) | 2025-06-18 |
| WO2019236879A1 (fr) | 2019-12-12 |
| CA3102645A1 (fr) | 2019-12-12 |
| CN112839647B (zh) | 2025-09-23 |
| JP2024037770A (ja) | 2024-03-19 |
| JP2021527125A (ja) | 2021-10-11 |
| US12338238B2 (en) | 2025-06-24 |
| US20210261540A1 (en) | 2021-08-26 |
| JP7576145B2 (ja) | 2024-10-30 |
| EP3801500B1 (fr) | 2025-03-05 |
| CN112839647A (zh) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| EP3833355A4 (fr) | Inhibiteurs de prmt5 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (fr) | Inhibiteurs de bcl-2 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| EP3793547A4 (fr) | Inhibiteurs de magl | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3856176A4 (fr) | Inhibiteurs de vap-1 | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3980011A4 (fr) | Inhibiteurs de sarm1 | |
| EP3773537A4 (fr) | Inhibiteurs de stat3 | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| EP3833664A4 (fr) | Inhibiteurs de smad3 |